Article Text

PDF
BCL-6 expression in mesenchymal tumours: an immunohistochemical and fluorescence in situ hybridisation study
  1. Matthew P Walters,
  2. Ellen D McPhail,
  3. Mark E Law,
  4. Andrew L Folpe
  1. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Professor Andrew L Folpe, Department of Laboratory Medicine and Pathology, Mayo Clinic, Hilton 11, Anatomic Pathology, 200 1st St SW, Rochester, MN 55905, USA; folpe.andrew{at}mayo.edu

Abstract

The BCL-6 proto-oncogene encodes a transcriptional repressor protein. Among normal tissues, BCL-6 expression is confined to germinal center B-cells and a subpopulation of T-helper cells. Little is known about BCL-6 expression in mesenchymal tissues. We examined a series of solitary fibrous tumor (SFT) and other mesenchymal tumors for BCL-6 expression. Immunohistochemistry for BCL-6 was performed on 64 mesenchymal tumors [26 SFT (19 benign/uncertain, 7 malignant), 6 synovial sarcomas (SS), 5 gastrointestinal stromal tumors (GIST), 5 malignant peripheral nerve sheath tumors (MPNST), 5 leiomyosarcomas (LMS), 9 leiomyomas (LM) 4 desmoid tumors (DT), 4 perineuriomas (PN)]. Nuclear immunoreactivity was considered positive. Six BCL-6 positive SFT were also tested for BCL-6 gene rearrangement/amplification by FISH. Nuclear expression of BCL-6 was seen in 13/26 SFT, 5/5 LMS, 1/9 LM, 5/6 SS, 1/5 GIST, 1/5 MPNST, 1/4 PN, and 0/5 DT. BCL-6 expression was significantly more frequent in malignant (6/7) as compared with benign/uncertain SFT (6/19) (p=0.02) and in LMS (5/5) as compared with LM (1/9) (p=0.003). FISH for BCL-6 rearrangement/amplification was negative in all tested cases. We have observed BCL-6 expression in 50% or more of SFT, SS, and LMS, and in a lesser percentage of LM, GIST, MPNST and PN. Significantly more frequent expression of BCL-6 in malignant compared with benign/uncertain SFT and in LMS compared with LM suggests abnormalities in the BCL-6 signaling pathway may contribute to malignant transformation in at least some mesenchymal tumors. It is unlikely that BCL-6 expression in mesenchymal tumors is due to BCL-6 gene amplification or rearrangement. amplification or rearrangement.

  • Solitary fibrous tumour
  • bcl-6
  • immunohistochemistry
  • sarcoma
  • haematopathology
  • immunophenotyping of leukaemias/lymphomas
  • lymphoma
  • malt-lymphoma
  • cytogenetics
  • in situ hybridisation
  • molecular genetics
  • neoplasms
  • aeromonas

Statistics from Altmetric.com

Footnotes

  • Competing interests None declared.

  • Ethics approval Ethics approval was provided by Mayo Clinic IRB.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.